Although you can enjoy much of this website without javascript, we highly recommend that you enable it
in order to experience all available features.

Cookies on What Doctors Don't Tell You

We set cookies so you can manage your account and navigate the site, and to remember your cookie preferences so that you don't keep getting this message. To accept cookies, just keep browsing,
otherwise use the links on the right to adjust your cookie settings or find out more.

New guidelines now define half of all adults as having dangerously high blood pressure, requiring drugs for the rest of their lives. Lynne McTaggart and Bryan Hubbard offer alternatives to your doctor's prescription

Lung cancer:

About the author:&nbsp

Lung cancer patients are usually prescribed either Tarceva (erlotinib) or Iressa (glefitinib)

Lung cancer patients are usually prescribed either Tarceva (erlotinib) or Iressa (glefitinib). Doctors will probably tell the unfortunate patient that the drugs stop the growth of the cancers by blocking the signaling from a molecule that's vital to the survival of the cancer cells. What he may not mention is that the drugs are effective in only 10 per cent of patients, especially those with non-small cell lung cancer (NSCLC), which is often contracted by non-smokers. And after a while, they are not effective at all - and, in fact, encourage the growth of the cancer. Oncologists know that the drugs seem to trigger fresh tumour growth, which is known as acquired or secondary resistance, but researchers are trying to figure out why this phenomenon occurs. They tracked six NSCLC patients who were given the drugs, and three developed fresh tumours. They weren't able to establish why the tumours develop such a virulent resistance to the drugs, but were able to confirm that the new mutations contained gene variants that "they had come across before". So that's a relief.